20 Jun
2024
16:30 E.S.T.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Read more

12 Jun
2024
10:27 E.S.T.

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Read more

04 Jun
2024
11:30 E.S.T.

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Read more

29 May
2024
16:30 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Read more

28 May
2024
16:30 E.S.T.

Cellectis Reports Financial Results for First Quarter 2024

Read more

24 May
2024
22:30 E.S.T.

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Read more

06 May
2024
02:05 E.S.T.

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Read more

02 May
2024
14:49 E.S.T.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Read more

29 Apr
2024
15:05 E.S.T.

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Read more

22 Apr
2024
11:16 E.S.T.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Read more